This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Sep 2026 quarter revenue up 20.8%, profit after tax up 30.4% year on year
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts less than Nifty Midcap 150 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On a consolidated basis for the quarter ended 30 September 2026, revenue from operations rose 20.8% to Rs 1,183.57 crore from Rs 979.94 crore, while profit after tax rose 30.4% to Rs 335.88 crore from Rs 257.49 crore a year earlier. Six-month consolidated revenue was Rs 2,122.01 crore and profit after tax Rs 573.06 crore. Walker Chandiok was approved as statutory auditor for 2027-28 to 2031-32, subject to shareholder approval.
Strong year-on-year sales and profit growth should support sentiment, though Rs 42.09 crore of tax-refund interest helped quarterly profit.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹1,184 Cr | ₹979.9 Cr | +20.8% |
| Operating profit | ₹386.6 Cr | ₹317.8 Cr | +21.6% |
| Profit after tax | ₹335.9 Cr | ₹257.5 Cr | +30.4% |
| EBITDA margin | 34.0% | 34.5% | −0.6 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.